Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

Open Access 01-12-2020 | Thyroid Cancer | Review

Molecular mechanisms of long non-coding RNAs in anaplastic thyroid cancer: a systematic review

Authors: Hilda Samimi, Sayed Mahmoud Sajjadi-Jazi, Soroush Seifirad, Rasha Atlasi, Habibollah Mahmoodzadeh, Mohammad Ali Faghihi, Vahid Haghpanah

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

anaplastic thyroid cancer (ATC) is one of the most lethal and aggressive cancers. Evidence has shown that the tumorigenesis of ATC is a multistep process involving the accumulation of genetic and epigenetic changes. Several studies have suggested that long non-coding RNAs (lncRNAs) may play an important role in the development and progression of ATC. In this article, we have collected the published reports about the role of lncRNAs in ATC.

Methods

“Scopus”, “Web of Science”, “PubMed”, “Embase”, etc. were systematically searched for articles published since 1990 to 2020 in English language, using the predefined keywords.

Results

961 papers were reviewed and finally 33 papers which fulfilled the inclusion and exclusion criteria were selected. Based on this systematic review, among a lot of evidences on examining the function of lncRNAs in thyroid cancer, there are only a small number of studies about the role of lncRNAs and their molecular mechanisms in the pathogenesis of ATC.

Conclusions

lncRNAs play a crucial role in regulation of different processes involved in the development and progression of ATC. Currently, just a few lncRNAs have been identified in ATC that may serve as prognosis markers such as GAS5, MIR22HG, and CASC2. Also, because of the dysregulation of Klhl14-AS, HOTAIRM1, and PCA3 during ATC development and progression, they may act as therapeutic targets. However, for most lncRNAs, only a single experiment has evaluated the expression profile in ATC tissues/cells. Therefore, further functional studies and expression profiling is needed to resolve this limitation and identify novel and valid biomarkers.
Literature
1.
Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7(10):569.PubMedCrossRef
2.
LiVolsi VA. Papillary thyroid carcinoma: an update. Mod Pathol. 2011;24(S2):1.CrossRef
3.
4.
5.
Samimi H, Fallah P, Sohi AN, Tavakoli R, Naderi M, Soleimani M, Larijani B, Haghpanah V. Precision medicine approach to anaplastic thyroid cancer: advances in targeted drug therapy based on specific signaling pathways. Acta Med Iran. 2017;55(3):200–8.PubMed
6.
Samimi H, Ghadami M, Khashayar P, Soleimani M, Larijani B, Haghpanah V. MicroRNAs networks in thyroid cancers: focus on miRNAs related to the fascin. J Diabetes Metab Disord. 2013;12(1):31.PubMedPubMedCentralCrossRef
7.
Smith N, Nucera C. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations. J Clin Endocrinol Metab. 2015;100(1):35–42.PubMedCrossRef
8.
Zhang R, Hardin H, Chen J, Guo Z, Lloyd RV. Non-coding RNAs in thyroid cancer. Endocr Pathol. 2016;27(1):12–20.PubMedCrossRef
9.
Sui F, Ji M, Hou P. Long non-coding RNAs in thyroid cancer: biological functions and clinical significance. Mol Cell Endocrinol. 2017;469:11.PubMedCrossRef
10.
Murugan AK, Munirajan AK, Alzahrani AS. Long noncoding RNAs: emerging players in thyroid cancer pathogenesis. Endocr Relat Cancer. 2018;25(2):R59–82.PubMedCrossRef
11.
Kim D, Lee WK, Jeong S, Seol M-Y, Kim H, Kim K-S, Lee EJ, Lee J, Jo YS. Upregulation of long noncoding RNA LOC100507661 promotes tumor aggressiveness in thyroid cancer. Mol Cell Endocrinol. 2016;431:36–45.PubMedCrossRef
12.
Guo L-J, Zhang S, Gao B, Jiang Y, Zhang X-H, Tian W-G, Hao S, Zhao J-J, Zhang G, Hu C-Y. Low expression of long non-coding RNA GAS5 is associated with poor prognosis of patients with thyroid cancer. Exp Mol Pathol. 2017;102(3):500–4.PubMedCrossRef
13.
Zhang H. Targeted inhibition of long non-coding RNA H19 blocks anaplastic thyroid carcinoma growth and metastasis. J Cell Mol Med. 2019;10(1):306–15.
14.
Wang Y, Hou Z, Li D. Long noncoding RNA UCA1 promotes anaplastic thyroid cancer cell proliferation via miR–135a–mediated c–myc activation. Mol Med Rep. 2018;18(3):3068–76.PubMed
15.
Wang Y, Hardin H, Chu Y-H, Esbona K, Zhang R, Lloyd RV. Long non-coding RNA expression in anaplastic thyroid carcinomas. Endocr Pathol. 2019;1:8.
16.
Chen J, Zhao D, Meng Q. Knockdown of HCP5 exerts tumor-suppressive functions by up-regulating tumor suppressor miR-128-3p in anaplastic thyroid cancer. Biomed Pharmacother. 2019;116:108966.PubMedCrossRef
17.
Credendino SC, Bellone ML, Lewin N, Amendola E, Sanges R, Basu S, Sepe R. A ceRNA Circuitry Involving the Long Noncoding RNA Klhl14-AS, Pax8, and Bcl2 Drives Thyroid Carcinogenesis. Cancer Res. 2019;79(22):5746–57.PubMedCrossRef
18.
Du P, Liu F, Liu Y, Shao M, Li X, Qin G. Linc00210 enhances the malignancy of thyroid cancer cells by modulating miR-195-5p/IGF1R/Akt axis. J Cell Physiol. 2020;235(2):1001–12.PubMedCrossRef
19.
Hou S, Lin Q, Guan F, Lin C. LncRNA TNRC6C-AS1 regulates UNC5B in thyroid cancer to influence cell proliferation, migration, and invasion as a competing endogenous RNA of miR-129-5p. J Cell Biochem. 2018;119(10):8304–16.PubMedCrossRef
20.
Li SQ, Zhao ZJ, Li Y, Zhang Y, Dong LY, Liang Y, Mao Y, Ma JF. The long noncoding RNA AK139328 promotes the oncogenesis in thyroid cancer. Int J Clin Exp Med. 2017;10(8):11894–902.
21.
Song WH, Lu BY, Huang YB, Dong HM, Ma XK, Zhu ZZ, Zhou R, Liu K, Huang W, Yan DQ, et al. Overexpression of long intergenic noncoding RNA LINC00312 inhibits the invasion and migration of thyroid cancer cells by down-regulating microRNA-197-3p. J Cell Biochem. 2017;37:4.
22.
Min X, Liu K, Zhu H, Zhang J. Long noncoding RNA LINC003121 inhibits proliferation and invasion of thyroid cancer cells by suppression of the phosphatidylinositol-3-Kinase (PI3K)/Akt Signaling Pathway. Med Sci Monit. 2018;24:4592–601.PubMedPubMedCentralCrossRef
23.
Liu H, Deng HY, Zhao YJ, Li C, Liang Y. LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling. J Exp Clin Cancer Res. 2018;37:23.CrossRef
24.
Chen L, Zhu J, Zhang LJ. Long non-coding RNA small nucleolar RNA host gene 7 is upregulated and promotes cell proliferation in thyroid cancer. Oncol Lett. 2019;18(5):4726–34.PubMedPubMedCentral
25.
Liu YC, Li JL, Li M, Li F, Shao Y, Wu LP. microRNA-510-5p promotes thyroid cancer cell proliferation, migration, and invasion through suppressing SNHG15. J Cell Biochem. 2019;120(7):11738–44.CrossRef
26.
Han CG, Huang Y, Qin L. Long non-coding RNA ZFAS1 as a novel potential biomarker for predicting the prognosis of thyroid cancer. Med Sci Monit. 2019;25:2984–92.PubMedPubMedCentralCrossRef
27.
Qin L, Luo JZ, Tang XL, Han CG. Identification of long noncoding RNA MIR22HG as a novel biomarker in thyroid cancer. J Cell Biochem. 2019;25(2):703–10.
28.
Xiong X, Zhu H, Chen X. Low expression of long noncoding RNA CASC2 indicates a poor prognosis and promotes tumorigenesis in thyroid carcinoma. Biomed Pharmacother. 2017;93:391–7.PubMedCrossRef
29.
Zhang H, Yu Y, Zhang K, Liu X, Dai Y, Jiao X. Targeted inhibition of long non-coding RNA H19 blocks anaplastic thyroid carcinoma growth and metastasis. Bioengineered. 2019;10(1):306–15.PubMedPubMedCentralCrossRef
30.
Hardin H, Helein H, Meyer K, Robertson S, Zhang R, Zhong W, Lloyd RV. Thyroid cancer stem-like cell exosomes: regulation of EMT via transfer of lncRNAs. J Cell Biochem. 2018;98(9):1133–42.
31.
Zhou Q, Chen J, Feng J, Wang J. Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR). Tumor Biol. 2016;37(3):3105–13.CrossRef
32.
Huang JK, Ma L, Song WH, Lu BY, Huang YB, Dong HM, Ma XK, Zhu ZZ, Zhou R. MALAT1 promotes the proliferation and invasion of thyroid cancer cells via regulating the expression of IQGAP1. Biomed Pharmacother. 2016;83:1–7.PubMedCrossRef
33.
Zhang R, Hardin H, Huang W, Chen J, Asioli S, Righi A, Maletta F, Sapino A, Lloyd RV. MALAT1 long non-coding RNA expression in thyroid tissues: analysis by in situ hybridization and real-time PCR. Endocr Pathol. 2017;28(1):7–12.PubMedPubMedCentralCrossRef
34.
Samimi H, Haghpanah V, Irani S, Arefian E, Sohi AN, Fallah P, Soleimani M. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor “BI-847325” on anaplastic thyroid carcinoma. DARU J Pharm Sci. 2019;27(1):1–7.CrossRef
35.
Gou L, Zou H, Li B. Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1. Cancer Biol Ther. 2019;20(11):1355–65.PubMedCrossRefPubMedCentral
36.
Liu C, Lin Y, Xu J, Chu H, Hao S, Liu X, Song X, Jiang L, Zheng H. Luteolin suppresses tumor progression through lncRNA BANCR and its downstream TSHR/CCND1 signaling in thyroid carcinoma. Sci Rep. 2017;10(9):9591–8.
37.
Liu XL, Fu QF, Li SJ, Liang N, Li F, Li CL, Sui CQ, Dionigi G, Sun H. LncRNA FOXD2-AS1 functions as a competing endogenous RNA to regulate TERT expression by sponging miR-7-5p in thyroid cancer. Front Endocrinol. 2019;10:207.CrossRef
38.
Wang X-m, Liu Y, Fan Y-x, Liu Z, Yuan Q-l, Jia M, Geng Z-s, Gu L. Lu X-b: LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway. Cancer Biol Ther. 2018;19(7):590–7.PubMedPubMedCentralCrossRef
39.
Fan M, Li X, Jiang W, Huang Y, Li J, Wang Z. A long non-coding RNA, PTCSC3, as a tumor suppressor and a target of miRNAs in thyroid cancer cells. Exp Ther Med. 2013;5(4):1143–6.PubMedPubMedCentralCrossRef
40.
Lu W, Xu Y, Xu J, Wang Z, Ye G. Identification of differential expressed lncRNAs in human thyroid cancer by a genome-wide analyses. Cancer Med. 2018;7(8):3935–44.PubMedPubMedCentralCrossRef
41.
Pellecchia S. The long non-coding RNA Prader Willi/Angelman Region RNA5 (PAR5) is downregulated in anaplastic thyroid carcinomas where it acts as a tumor suppressor by reducing EZH2 Activity. Cancers. 2020;12:1.CrossRef
42.
Lei H, Gao Y, Xu X. LncRNA TUG1 influences papillary thyroid cancer cell proliferation, migration and EMT formation through targeting miR-145. Acta Biochim Biophys Sin. 2017;49(7):588–97.PubMedCrossRef
43.
Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai M-C, Hung T, Argani P, Rinn JL. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464(7291):1071.PubMedPubMedCentralCrossRef
44.
He X, Liu Z, Su J, Yang J, Yin D, Han L, De W, Guo R. Low expression of long noncoding RNA CASC2 indicates a poor prognosis and regulates cell proliferation in non-small cell lung cancer. Tumor Biol. 2016;37(7):9503–10.CrossRef
45.
Liu Z, Wang W, Jiang J, Bao E, Xu D, Zeng Y, Tao L, Qiu J. Downregulation of GAS5 promotes bladder cancer cell proliferation, partly by regulating CDK6. PLoS ONE. 2013;8(9):e73991.PubMedPubMedCentralCrossRef
46.
Hamada S, Satoh K, Miura S, Hirota M, Kanno A, Masamune A, Kikuta K, Kume K, Unno J, Egawa S. miR-197 induces epithelial–mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. J Cell Physiol. 2013;228(6):1255–63.PubMedCrossRef
47.
Stairs DB, Bayne LJ, Rhoades B, Vega ME, Waldron TJ, Kalabis J, Klein-Szanto A, Lee J-S, Katz JP, Diehl JA. Deletion of p120-catenin results in a tumor microenvironment with inflammation and cancer that establishes it as a tumor suppressor gene. Cancer Cell. 2011;19(4):470–83.PubMedPubMedCentralCrossRef
48.
Zou D, Wang D, Li R, Tang Y, Yuan L, Long X, Zhou Q. MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK. Tumor Biol. 2015;36(9):6725–32.CrossRef
49.
Björklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 2005;1755(1):37–69.PubMed
50.
Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochimica Biochim Biophys Acta. 2012;1825(1):29–36.
51.
Baldini E, Toller M, Graziano F, Russo F, Pepe M, Biordi L, Marchioni E, Curcio F, Ulisse S, Ambesi-Impiombato F. Expression of matrix metalloproteinases and their specific inhibitors in normal and different human thyroid tumor cell lines. Thyroid. 2004;14(11):881–8.PubMedCrossRef
52.
Su W, Feng S, Chen X, Yang X, Mao R, Guo C, Wang Z, Thomas DG, Lin J, Reddy RM. Silencing of long noncoding RNA MIR22HG triggers cell survival/death signaling via oncogenes YBX1, MET, and p21 in lung cancer. Cancer Res. 2018;78(12):3207–19.PubMedPubMedCentralCrossRef
53.
Liu Y, Li J, Li F, Li M, Shao Y, Wu L. SNHG15 functions as a tumor suppressor in thyroid cancer. J Cell Biochem. 2019;120(4):6120–6.PubMedCrossRef
54.
Li F, Hu C-P. Long non-coding RNA urothelial carcinoma associated 1 (UCA1): insight into its role in human diseases. Crit Rev Eukaryot Gene Expr. 2015;25:3.
55.
Wang F, Li X, Xie X, Zhao L, Chen W. UCA1, a non-protein‐coding RNA up‐regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. FEBS Lett. 2008;582(13):1919–27.PubMedCrossRef
56.
Zhang S, Dong X, Ji T, Chen G, Shan L. Long non-coding RNA UCA1 promotes cell progression by acting as a competing endogenous RNA of ATF2 in prostate cancer. Am J Transl Res. 2017;9(2):366.PubMedPubMedCentral
57.
Jiao C, Song Z, Chen J, Zhong J, Cai W, Tian S, Chen S, Yi Y, Xiao Y. lncRNA-UCA1 enhances cell proliferation through functioning as a ceRNA of Sox4 in esophageal cancer. Oncol Rep. 2016;36(5):2960–6.PubMedCrossRef
58.
Wang Z-Q, Cai Q, Hu L, He C-Y, Li J-F, Quan Z-W, Liu B-Y, Li C, Zhu Z-G. Long noncoding RNA UCA1 induced by SP1 promotes cell proliferation via recruiting EZH2 and activating AKT pathway in gastric cancer. Cell Death Dis. 2017;8(6):e2839–9.PubMedPubMedCentralCrossRef
59.
Liu Y, Zong Z-H, Guan X, Wang L-l, Zhao Y. The role of long non-coding RNA PCA3 in epithelial ovarian carcinoma tumorigenesis and progression. Gene. 2017;633:42–7.PubMedCrossRef
60.
Sajjadi E, Atashi A, Tajrishi MAMH, Saei Z. Gene expression analysis of noncoding PCA3 gene in patients with chronic myeloid leukemia. J Cancer Res Ther. 2018;14(5):1079.PubMedCrossRef
61.
Luo Y, He Y, Ye X, Song J, Wang Q, Li Y, Xie X. High expression of long noncoding RNA HOTAIRM1 is associated with the proliferation and migration in pancreatic ductal adenocarcinoma. Pathol Oncol Res. 2019;25(4):1567–77.PubMedCrossRef
62.
Li Q, Dong C, Cui J, Wang Y, Hong X. Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme. J Exp Clin Cancer Res. 2018;37(1):1–15.CrossRef
63.
Wan L, Kong J, Tang J, Wu Y, Xu E, Lai M, Zhang H. HOTAIRM 1 as a potential biomarker for diagnosis of colorectal cancer functions the role in the tumour suppressor. J Cell Mol Med. 2016;20(11):2036–44.PubMedPubMedCentralCrossRef
64.
Zhao W, Li L. SP1-induced upregulation of long non-coding RNA HCP5 promotes the development of osteosarcoma. Pathol Res Pract. 2019;215(3):439–45.PubMedCrossRef
65.
Yu Y, Shen H, Fang D, Meng Q, Xin Y. LncRNA HCP5 promotes the development of cervical cancer by regulating MACC1 via suppression of microRNA-15a. Eur Rev Med Pharmacol Sci. 2018;22(15):4812–9.PubMed
66.
Teng H, Wang P, Xue Y, Liu X, Ma J, Cai H, Xi Z, Li Z, Liu Y. Role of HCP5-miR-139-RUNX1 feedback loop in regulating malignant behavior of glioma cells. Mol Ther. 2016;24(10):1806–22.PubMedPubMedCentralCrossRef
67.
Li XL, Yu H, Wu GS. Investigating the genetic association of HCP 5, SPATA 2, TNIP 1, TNFAIP 3 and COG 6 with psoriasis in C hinese population. Int J Immunogenet. 2014;41(6):503–7.PubMedCrossRef
68.
Kim J-J, Yun SW, Yu JJ, Yoon KL, Lee K-Y, Kil H-R, Kim GB, Han M-K, Song MS, Lee HD. A genome-wide association analysis identifies NMNAT2 and HCP5 as susceptibility loci for Kawasaki disease. J Hum Genet. 2017;62(12):1023–9.PubMedCrossRef
69.
70.
An X-Z, Zhao Z-G, Luo Y-X, Zhang R, Tang X-Q, Hao D-L, Zhao X, Lv X, Liu D-P. Netrin-1 suppresses the MEK/ERK pathway and ITGB4 in pancreatic cancer. Oncotarget. 2016;7(17):24719.PubMedPubMedCentralCrossRef
71.
Chen Z, Jia S, Li D, Cai J, Tu J, Geng B, Guan Y, Cui Q, Yang J. Silencing of long noncoding RNA AK139328 attenuates ischemia/reperfusion injury in mouse livers. PLoS ONE. 2013;8:11.CrossRef
72.
Garcia C, Buffet C, El Khattabi L, Rizk-Rabin M, Perlemoine K, Ragazzon B, Bertherat J, Cormier F, Groussin L. MET overexpression and activation favors invasiveness in a model of anaplastic thyroid cancer. Oncotarget. 2019;10(23):2320.PubMedPubMedCentralCrossRef
73.
Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z, Deng X, Chen H, Shen B, Peng C. Amplification of long noncoding RNA ZFAS1 promotes metastasis in hepatocellular carcinoma. Cancer Res. 2015;75(15):3181–91.PubMedCrossRef
74.
Zhang H, Cai Y, Zheng L, Zhang Z, Lin X, Jiang N. Long noncoding RNA NEAT1 regulate papillary thyroid cancer progression by modulating miR-129‐5p/KLK7 expression. J Cell Physiol. 2018;233(10):6638–48.PubMedCrossRef
75.
Zhang P, Zuo H, Ozaki T, Nakagomi N, Kakudo K. Cancer stem cell hypothesis in thyroid cancer. Pathol Int. 2006;56(9):485–9.PubMedCrossRef
76.
Carina V, Zito G, Pizzolanti G, Richiusa P, Criscimanna A, Rodolico V, Tomasello L, Pitrone M, Arancio W, Giordano C. Multiple pluripotent stem cell markers in human anaplastic thyroid cancer: the putative upstream role of SOX2. Thyroid. 2013;23(7):829–37.PubMedPubMedCentralCrossRef
77.
Haghpanah V, Fallah P, Naderi M, Tavakoli R, Soleimani M, Larijani B. Cancer stem-like cell behavior in anaplastic thyroid cancer: A challenging dilemma. Life Sci. 2016;146:34–9.PubMedCrossRef
78.
Guo Z, Hardin H, Lloyd RV. Cancer stem-like cells and thyroid cancer. Endocr Relat Cancer. 2014;21(5):T285–300.PubMedCrossRef
79.
Mitsutake N, Iwao A, Nagai K, Namba H, Ohtsuru A, Saenko V, Yamashita S. Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. Endocrinology. 2007;148(4):1797–803.PubMedCrossRef
80.
Jung CW, Han KH, Seol H, Park S, Koh JS, Lee S-S, Kim MJ, Choi IJ, Myung JK. Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma. Int J Clin Exp Pathol. 2015;8(1):560.PubMedPubMedCentral
81.
Floor S, Van Staveren W, Larsimont D, Dumont J, Maenhaut C. Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating–cancer stem cells: distinct, overlapping or same populations. Oncogene. 2011;30(46):4609.PubMedCrossRef
82.
83.
Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15(1):7.PubMedCrossRef
84.
85.
Pan Y, Li C, Chen J, Zhang K, Chu X, Wang R, Chen L. The emerging roles of long noncoding RNA ROR (lincRNA-ROR) and its possible mechanisms in human cancers. Cell Physiol Biochem. 2016;40(1–2):219–29.PubMedCrossRef
86.
Aiello A, Pandini G, Frasca F, Conte E, Murabito A, Sacco A, Genua M, Vigneri R, Belfiore A. Peroxisomal proliferator-activated receptor-γ agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology. 2006;147(9):4463–75.PubMedCrossRef
87.
Wang Y, Xu Z, Jiang J, Xu C, Kang J, Xiao L, Wu M, Xiong J, Guo X, Liu H. Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal. Dev Cell. 2013;25(1):69–80.PubMedCrossRef
88.
Gao S, Wang P, Hua Y, Xi H, Meng Z, Liu T, Chen Z, Liu L. ROR functions as a ceRNA to regulate Nanog expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer. Oncotarget. 2016;7(2):1608.PubMedCrossRef
89.
Huang C, Liu S, Wang H, Zhang Z, Yang Q, Gao F. LncRNA PVT1 overexpression is a poor prognostic biomarker and regulates migration and invasion in small cell lung cancer. Am J Transl Res. 2016;8(11):5025.PubMedPubMedCentral
90.
Iden M, Fye S, Li K, Chowdhury T, Ramchandran R, Rader JS. The lncRNA PVT1 contributes to the cervical cancer phenotype and associates with poor patient prognosis. PLoS One. 2016;11(5):e0156274.PubMedPubMedCentralCrossRef
91.
Masudo K, Suganuma N, Nakayama H, Oshima T, Rino Y, Iwasaki H, Matsuzu K, Sugino K, Ito K, Kondo T. EZH2 overexpression as a useful prognostic marker for aggressive behaviour in thyroid cancer. In vivo. 2018;32(1):25–31.PubMedPubMedCentral
92.
Borbone E, Troncone G, Ferraro A, Jasencakova Z, Stojic L, Esposito F, Hornig N, Fusco A, Orlando V. Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas. J Clin Endocrinol Metab. 2011;96(4):1029–38.PubMedCrossRef
93.
94.
Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA. 2003;100(20):11606–11.PubMedCrossRefPubMedCentral
95.
Ma X-Y, Wang J-H, Wang J-L, Ma CX, Wang X-C, Liu F-S. Malat1 as an evolutionarily conserved lncRNA, plays a positive role in regulating proliferation and maintaining undifferentiated status of early-stage hematopoietic cells. BMC Genom. 2015;16(1)::676.CrossRef
96.
Heery R, Finn S, Cuffe S, Gray S. Long non-coding RNAs: key regulators of epithelial-mesenchymal transition, tumour drug resistance and cancer stem cells. Cancers. 2017;9(4):38.PubMedCentralCrossRef
97.
Jiao F, Hu H, Han T, Yuan C, Wang L, Jin Z, Guo Z, Wang L. Long noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cells. Int J Mol Sci. 2015;16(4):6677–93.PubMedPubMedCentralCrossRef
98.
Hardin H, Guo Z, Shan W, Montemayor-Garcia C, Asioli S, Yu X-M, Harrison AD, Chen H, Lloyd RV. The roles of the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progression. Am J Pathol. 2014;184(8):2342–54.PubMedPubMedCentralCrossRef
99.
Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15.PubMedCrossRef
100.
Zhang R, Hardin H, Huang W, Chen J, Asioli S, Righi A, Maletta F, Sapino A, Lloyd RV. MALAT1 long non-coding RNA expression in thyroid tissues: analysis by in situ hybridization and real-time PCR. Endocr Pathol. 2017;28(1):7–12.PubMedPubMedCentralCrossRef
101.
Dongre A, Weinberg RA. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2018;20:69.CrossRef
102.
Huang J-K, Ma L, Song W-H, Lu B-Y, Huang Y-B, Dong H-M, Ma X-K. MALAT1 promotes the proliferation and invasion of thyroid cancer cells via regulating the expression of IQGAP1. Biomed Pharmacother. 2016;83:1–7.PubMedCrossRef
103.
Zeng F, Jiang W, Zhao W, Fan Y, Zhu Y, Zhang H. Ras GTPase-Activating-Like Protein IQGAP1 (IQGAP1) promotes breast cancer proliferation and invasion and correlates with poor clinical outcomes. Med Sci Monit. 2018;24:3315.PubMedPubMedCentralCrossRef
104.
Smith A, Teknos TN, Pan Q. Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncol. 2013;49(4):287–92.PubMedCrossRef
105.
Gumbiner BM. Regulation of cadherin adhesive activity. J Ccell Biol. 2000;148(3):399–404.CrossRef
106.
Qi Y, Ooi HS, Wu J, Chen J, Zhang X, Tan S, Yu Q, Li Y-Y, Kang Y, Li H. MALAT1 long ncRNA promotes gastric cancer metastasis by suppressing PCDH10. Oncotarget. 2016;7(11):12693.PubMedPubMedCentralCrossRef
107.
Wang D, Ding L, Wang L, Zhao Y, Sun Z, Karnes RJ, Zhang J, Huang H. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer. Oncotarget. 2015;6(38)::41045.CrossRef
108.
Kim SH, Kim SH, Yang WI, Kim SJ, Yoon SO. Association of the long non-coding RNA MALAT1 with the polycomb repressive complex pathway in T and NK cell lymphoma. Oncotarget. 2017;8(19):31305.PubMedPubMedCentralCrossRef
109.
Su F, He W, Chen C, Liu M, Liu H, Xue F, Bi J, Xu D, Zhao Y, Huang J. The long non-coding RNA FOXD2-AS1 promotes bladder cancer progression and recurrence through a positive feedback loop with Akt and E2F1. Cell Death Dis. 2018;9(2):1–17.CrossRef
110.
Xu T-p, Wang W-y, Ma P, Shuai Y, Zhao K, Wang Y-f, Li W, Xia R, Chen W. Upregulation of the long noncoding RNA FOXD2-AS1 promotes carcinogenesis by epigenetically silencing EphB3 through EZH2 and LSD1, and predicts poor prognosis in gastric cancer. Oncogene. 2018;37(36):5020–36.PubMedCrossRef
111.
Hou M, Zhan Y, Sheng X, Liu X, Fu Q, Li S, Liang N, Li F, Li C, Sui C, et al. LncRNA FOXD2-AS1 Functions as a Competing Endogenous RNA to Regulate TERT Expression by Sponging miR-7-5p in Thyroid Cancer. J Cell Biochem. 2019;10:207.
112.
Meyers-Needham M, Ponnusamy S, Gencer S, Jiang W, Thomas RJ, Senkal CE, Ogretmen B. Concerted functions of HDAC1 and microRNA‐574‐5p repress alternatively spliced ceramide synthase 1 expression in human cancer cells. EMBO Mol Med. 2012;4(2)::78–92.CrossRef
113.
Ji S, Ye G, Zhang J, Wang L, Wang T, Wang Z, Zhang T, Wang G, Guo Z, Luo Y. miR-574-5p negatively regulates Qki6/7 to impact β-catenin/Wnt signalling and the development of colorectal cancer. Gut. 2013;62(5):716–26.PubMedCrossRef
114.
Zhang X-Q, Sun S, Lam K-F, Kiang KM-Y, Pu JK-S, Ho AS-W, Lui W-M, Fung C-F, Wong T-S, Leung GK-K. A long non-coding RNA signature in glioblastoma multiforme predicts survival. Neurobiol Dis. 2013;58:123–31.PubMedCrossRef
115.
Zhai H-Y, Sui M-H, Yu X, Qu Z, Hu J-C, Sun H-Q, Zheng H-T, Zhou K, Jiang L-X. Overexpression of long non-coding RNA TUG1 promotes colon cancer progression. Med Sci Monit. 2016;22:3281.PubMedPubMedCentralCrossRef
Metadata
Title
Molecular mechanisms of long non-coding RNAs in anaplastic thyroid cancer: a systematic review
Authors
Hilda Samimi
Sayed Mahmoud Sajjadi-Jazi
Soroush Seifirad
Rasha Atlasi
Habibollah Mahmoodzadeh
Mohammad Ali Faghihi
Vahid Haghpanah
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01439-w

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Primary research

RETRACTED ARTICLE: Long non-coding RNA SATB2-AS1 inhibits microRNA-155-3p to suppress breast cancer cell growth by promoting breast cancer metastasis suppressor 1-like

Primary research

Elevated expression of RUNX3 co-expressing with EZH2 in esophageal cancer patients from India

Primary research

The expression profiles and prognostic values of HSPs family members in Head and neck cancer

Primary research

Genomic profiling of colorectal cancer with isolated lung metastasis

Primary research

Molecular interaction and cellular studies on combination photodynamic therapy with rutoside for melanoma A375 cancer cells: an in vitro study

Primary research

The novel long non-coding RNA LATS2-AS1-001 inhibits gastric cancer progression by regulating the LATS2/YAP1 signaling pathway via binding to EZH2
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits